Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2014, Article ID 703238, 16 pages
http://dx.doi.org/10.1155/2014/703238
Review Article

The Study of Pyridazine Compounds on Prostanoids: Inhibitors of COX, cAMP Phosphodiesterase, and TXA2 Synthase

Department of Pharmacy, GRD (PG) Institute of Management and Technology, 214 Rajpur Road, Dehradun 248009, India

Received 15 May 2013; Revised 3 October 2013; Accepted 3 October 2013; Published 13 March 2014

Academic Editor: Huu Hao Ngo

Copyright © 2014 Mohammad Asif. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Asif, “Some recent approaches of biologically active substituted pyridazine and phthalazine drugs,” Current Medicinal Chemistry, vol. 19, no. 18, pp. 2984–2991, 2012. View at Publisher · View at Google Scholar
  2. C. M. Allerton, M. D. Andrews, J. Blagg et al., “Design and synthesis of pyridazinone-based 5-HT2C agonists,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 19, pp. 5791–5795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Bansal, D. Kumar, R. Carron, and C. de la Calle, “Synthesis and vasodilatory activity of some amide derivatives of 6-(4-carboxymethyloxyphenyl)-4,5-dihydro-3(2H)-pyridazinone,” European Journal of Medicinal Chemistry, vol. 44, no. 11, pp. 4441–4447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Kumar, R. Carron, C. D. La Calle, D. P. Jindal, and R. Bansal, “Synthesis and evaluation of 2-substituted-6-phenyl-4,5-dihydropyridazin- 3(2H)-ones as potent inodilators,” Acta Pharmaceutica, vol. 58, no. 4, pp. 393–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. I. G. Rathish, K. Javed, S. Bano, S. Ahmad, M. S. Alam, and K. K. Pillai, “Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives,” European Journal of Medicinal Chemistry, vol. 44, no. 6, pp. 2673–2678, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Asif, A. Singh, and A. A. Siddiqui, “The effect of pyridazine compounds on the cardiovascular system,” Medicinal Chemistry Research, vol. 21, no. 11, pp. 3336–3346, 2012. View at Publisher · View at Google Scholar
  7. E. Sotelo, A. Coelho, and E. Raviña, “Pyridazine derivatives 32: stille-based approaches in the synthesis of 5-substituted-6-phenyl-3(2H)-pyridazinones,” Chemical and Pharmaceutical Bulletin, vol. 51, no. 4, pp. 427–430, 2003. View at Google Scholar · View at Scopus
  8. T. Wang, Y. Dong, L. Wang, and Z. Chen, “Synthesis and bioactivity of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives,” Drug Research, vol. 57, no. 10, pp. 641–646, 2007. View at Google Scholar · View at Scopus
  9. T. Wang, Y. Dong, L. Wang, B. Xiang, Z. Chen, and L. Qu, “Design, synthesis and structure-activity relationship studies of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives as cardiotonic agents,” Drug Research, vol. 58, no. 11, pp. 569–573, 2008. View at Google Scholar · View at Scopus
  10. O. Boutaud, D. M. Aronoff, J. H. Richardson, L. J. Marnett, and J. A. Oates, “Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 10, pp. 7130–7135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Brideau, S. Kargman, S. Liu et al., “A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors,” Inflammation Research, vol. 45, no. 2, pp. 68–74, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Brune and B. Hinz, “Selective cyclooxygenase-2 inhibitors: similarities and differences,” Scandinavian Journal of Rheumatology, vol. 33, no. 1, pp. 1–6, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Collins, R. Peto, C. Baigent, and P. Sleight, “Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction,” New England Journal of Medicine, vol. 336, no. 12, pp. 847–860, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Dannhardt and S. Laufer, “Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore?” Current Medicinal Chemistry, vol. 7, no. 11, pp. 1101–1112, 2000. View at Google Scholar · View at Scopus
  15. J. A. Balfour, A. Fitton, and L. B. Barradell, “Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions,” Drugs, vol. 51, no. 4, pp. 639–657, 1996. View at Google Scholar · View at Scopus
  16. J. Jin and S. P. Kunapuli, “Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 14, pp. 8070–8074, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. A. L. Jones, “Mechanism of action and value of N-Acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review,” Journal of Toxicology, vol. 36, no. 4, pp. 277–285, 1998. View at Google Scholar · View at Scopus
  18. P. Jüni, A. W. S. Rutjes, and P. A. Dieppe, “Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?” British Medical Journal, vol. 324, no. 7349, pp. 1287–1288, 2002. View at Google Scholar · View at Scopus
  19. A. S. Kalgutkar, A. B. Marnett, B. C. Crews, R. P. Remmel, and L. J. Marnett, “Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors,” Journal of Medicinal Chemistry, vol. 43, no. 15, pp. 2860–2870, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Kalgutkar, S. W. Rowlinson, B. C. Crews, and L. J. Marnett, “Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 4, pp. 521–524, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Takaya, M. Sato, K. Terashima, H. Tanizawa, and Y. Maki, “A new nonsteroidal analgesic-antiinflammatory agent. Synthesis and activity of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone and related compounds,” Journal of Medicinal Chemistry, vol. 22, no. 1, pp. 53–58, 1979. View at Google Scholar · View at Scopus
  22. M. Sato, Y. Ishizuka, and A. Yamaguchi, “Pharmacological investigations of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M 73101), a new analgesic and anti-inflammatory drug,” Drug Research, vol. 31, no. 10, pp. 1738–1745, 1981. View at Google Scholar · View at Scopus
  23. M. Sato and A. Yamaguchi, “Studies on mechanisms of action of emorfazone. Effects on the release of bradykinin-like substance in thermic edema of rat paws,” Drug Research, vol. 32, no. 4, pp. 379–382, 1982. View at Google Scholar · View at Scopus
  24. M. Şüküroğlu, E. Küpeli, E. Banoğlu, S. Ünlü, E. Yeşilada, and M. F. Şahin, “Synthesis and analgesic activity of some 4,6-disubstituted-3(2H)-pyridazinone derivatives,” Drug Research, vol. 56, no. 5, pp. 337–345, 2006. View at Google Scholar
  25. V. Dal Piaz, M. P. Giovannoni, G. Ciciani et al., “4,5-Functionalized 6-phenyl-3(2H)-pyridazinones: synthesis and evaluation of antinociceptive activity,” European Journal of Medicinal Chemistry, vol. 31, no. 1, pp. 65–70, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Balkan, F. Özkanli, O. Ünsal, Z. Gören, and B. Terzioǧlu, “Studies on Some 3-Oxo-5-benzylidene-6-methyl-(4H) -2-substitutedpyridazines with Antinociceptive and Antiinflammatory Activities,” Fabad Journal of Pharmaceutical Sciences, vol. 28, no. 1, pp. 19–25, 2003. View at Google Scholar · View at Scopus
  27. R. H. Richard, B. Lawrence, S. Sekhar et al., “ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 3, pp. 904–912, 2004. View at Publisher · View at Google Scholar
  28. D. S. Dogruer, V. Sahin, E. Kupeli, and E. Yesilada, “Synthesis and analgesic and anti-inflammatory activity of new pyridazinones,” Turkish Journal of Chemistry, vol. 27, pp. 727–738, 2003. View at Google Scholar
  29. D. S. Doǧruer, S. Ünlü, E. Küpeli, E. Banogǧlu, and M. F. Şahin, “Synthesis of 2-[5,6-diphenyl-3(2H)-pyridazinone-2-yl]acetamide and 3-[5,6-diphenyl-3(2H)-pyridazinone-2-yl]propanamide derivatives as analgesic and anti-inflammatory agents,” Turkish Journal of Pharmaceutical Sciences, vol. 4, no. 2, pp. 57–70, 2007. View at Google Scholar · View at Scopus
  30. D. S. Doğruer, M. F. Şahin, S. Ünlü, and S. Ito, “Studies on some 3(2H)-pyridazinone derivatives with antinociceptive activity,” Archiv der Pharmazie, vol. 333, pp. 79–86, 2000. View at Google Scholar
  31. E. Banoǧlu, M. Şüküroǧlu, B. Çalişkan Ergün, S. Nacak Baytaş, E. Aypar, and M. Ark, “Synthesis of the amide derivatives of 3-[1-(3-pyridazinyl)-5-phenyl-1H- pyrazole-3-yl]propanoic acids as potential analgesic compounds,” Turkish Journal of Chemistry, vol. 31, no. 6, pp. 677–687, 2007. View at Google Scholar · View at Scopus
  32. M. Süküroglu, B. Çaliskan Ergün, S. Ünlü et al., “Synthesis, analgesic, and anti-inflammatory activities of [6-(3,5-dimethyl-4-chloropyrazole-1-yl)-3(2H)-pyridazinon-2-yl]acetamides,” Archives of Pharmacal Research, vol. 28, no. 5, pp. 509–517, 2005. View at Google Scholar · View at Scopus
  33. G. Cignarella, G. Grella, and M. Loriga, “Unexpected antiinflammatory activity in rigid structures derived from antihypertensive 6-arylpyridazinones,” Farmaco, Edizione Scientifica, vol. 33, no. 11, pp. 866–874, 1978. View at Google Scholar · View at Scopus
  34. M. Gökçe, M. S. Colak, E. Küpeli, and M. F. Sahin, “Synthesis and analgesic and anti-inflammatory activity of 6-phenyl/(4-methylphenyl)-3(2H)-pyridazinon-2-propionamide derivatives,” Arzneimittelforschung, vol. 59, no. 7, pp. 357–363, 2009. View at Google Scholar
  35. M. Gökçe, S. Utku, and E. Küpeli, “Synthesis and analgesic and anti-inflammatory activities 6-substituted-3(2H)-pyridazinone-2-acetyl-2-(p-substituted/nonsubstituted benzal)hydrazone derivatives,” European Journal of Medicinal Chemistry, vol. 44, no. 9, pp. 3760–3764, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Biancalani, M. P. Giovannoni, S. Pieretti et al., “Further studies on arylpiperazinyl alkyl pyridazinones: discovery of an exceptionally potent, orally active, antinociceptive agent in thermally induced pain,” Journal of Medicinal Chemistry, vol. 52, no. 23, pp. 7397–7409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Mikashima, T. Nakao, and K. Goto, “Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent. II. Inhibition of platelet phosphodiesterase,” Thrombosis Research, vol. 35, no. 5, pp. 589–594, 1984. View at Google Scholar · View at Scopus
  38. P. H. Chanh, B. Lasserre, A. Pham Huu Chanh et al., “A selective inhibitor of thromboxane synthetase activity of rabbit heart tissue: a pyridazinic derivative,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 33, no. 2, pp. 143–147, 1988. View at Google Scholar · View at Scopus
  39. G. Q. Zeng, X. S. Wang, D. X. Sun et al., “Effects of 6-(alpha alpha-diphenylacetylpiperazinyl) phenyl-5-methyl-4,5-dihydro-3 (2H)-pyridazinone on rabbit platelet aggregation and TXB2, cAMP production,” Acta Pharmaceutica Sinica, vol. 28, no. 4, pp. 256–259, 1993. View at Google Scholar · View at Scopus
  40. K. Tsubaki, K. Taniguchi, S. Tabuchi et al., “A novel pyridazinone derivative as a nonprostanoid PGI2 agonist,” Bioorganic and Medicinal Chemistry Letters, vol. 10, no. 24, pp. 2787–2790, 2000. View at Google Scholar · View at Scopus
  41. O. Azzolina, V. Dal Piaz, S. Collina, M. P. Giovannoni, and C. Tadini, “Chiral resolution and absolute configuration of the enantiomers of 5-acetyl-2-methyl-4-methylsulfinyl-6-phenyl-3(2H)-pyridazinone and evaluation of their platelet aggregation inhibitory activity,” Chirality, vol. 9, no. 7, pp. 681–685, 1997. View at Google Scholar
  42. S. C. Cherng, W. H. Huang, C. Y. Shiau, A. R. Lee, and T. C. Chou, “Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative,” European Journal of Pharmacology, vol. 532, no. 1-2, pp. 32–37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Asif, D. Singh, and A. Singh, “Analgesic activity of some 6-phenyl-4-substituted benzylidene tetrahydro pyridazin-3(2H)-ones,” Global Journal of Pharmacology, vol. 5, no. 1, pp. 18–22, 2011. View at Google Scholar · View at Scopus
  44. E. N. Amin, A. M. Abdel-Alim, S. G. Abdel-Moty, A. A. El-Shorbagi, and M. S. Abdel-Rahman, “Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities,” Archives of Pharmacal Research, vol. 33, no. 1, pp. 25–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. O. U. Tan, K. Özadali, Ö. Y. Ilyurt, H. Kayir, T. Uzbay, and A. Balkan, “Synthesis and evaluation of the analgesic activity of some new isoxazolo[4,5-d]pyridazin-4(5H)-one derivatives,” Turkish Journal of Chemistry, vol. 35, no. 1, pp. 121–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. S. V. Morant, M. J. Shield, P. G. Davey, and T. M. MacDonald, “A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac,” Pharmacoepidemiology and Drug Safety, vol. 11, no. 5, pp. 393–400, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Navidpour, H. Shafaroodi, K. Abdi et al., “Design, synthesis, and biological evaluation of substituted 3-alkylthio-4,5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors,” Bioorganic and Medicinal Chemistry, vol. 14, no. 8, pp. 2507–2517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. N. M. Maalouf, M. A. Cameron, O. W. Moe, and K. Sakhaee, “Novel insights into the pathogenesis of uric acid nephrolithiasis,” Current Opinion in Nephrology and Hypertension, vol. 13, no. 2, pp. 181–189, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. W. McNeely and K. L. Goa, “Diclofenac-potassium in migraine,” Drugs, vol. 57, no. 6, pp. 991–1003, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Meager, “Cytokine regulation of cellular adhesion molecule expression in inflammation,” Cytokine and Growth Factor Reviews, vol. 10, no. 1, pp. 27–39, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. S. G. Louie, B. Park, and H. Yoon, “Biological response modifiers in the management of rheumatoid arthritis,” American Journal of Health-System Pharmacy, vol. 60, no. 4, pp. 346–355, 2003. View at Google Scholar · View at Scopus
  52. J. Marjoribanks, M. Proctor, C. Farquhar, and R. S. Derks, “Nonsteroidal anti-inflammatory drugs for dysmenorrhoea,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD001751, 2010. View at Google Scholar · View at Scopus
  53. P. Patrignani, M. R. Panara, A. Greco et al., “Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases,” Journal of Pharmacology and Experimental Therapeutics, vol. 271, no. 3, pp. 1705–1712, 1994. View at Google Scholar · View at Scopus
  54. A. K. Pedersen and G. A. FitzGerald, “Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase,” New England Journal of Medicine, vol. 311, no. 19, pp. 1206–1211, 1984. View at Google Scholar · View at Scopus
  55. J. F. T. Glasgow and B. Middleton, “Reye syndrome Insights on causation and prognosis,” Archives of Disease in Childhood, vol. 85, no. 5, pp. 351–353, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. C. D. Loftin, D. B. Trivedi, and R. Langenbach, “Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus,” Journal of Clinical Investigation, vol. 110, no. 4, pp. 549–557, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. C. N. Serhan and N. Chiang, “Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomics,” Rheumatic Disease Clinics of North America, vol. 30, no. 1, pp. 69–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. S. S. Shin, Y. Byun, K. M. Lim et al., “In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-Aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives,” Journal of Medicinal Chemistry, vol. 47, no. 4, pp. 792–804, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. S. S. Shin, M. Noh, Y. J. Byun et al., “2,2-dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 2, pp. 165–168, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. A. S. Worobec, “Treatment of systemic mast cell disorders,” Hematology/Oncology Clinics of North America, vol. 14, no. 3, pp. 659–687, 2000. View at Google Scholar · View at Scopus
  61. B. Rigas and S. J. Shiff, “Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction,” Medical Hypotheses, vol. 54, no. 2, pp. 210–215, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. M. CruzCorrea, L. M. Hylind, K. E. Romans, S. V. Booker, and F. M. Giardiello, “Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study,” Gastroenterology, vol. 122, no. 3, pp. 641–645, 2002. View at Google Scholar · View at Scopus
  63. J. J. Deeks, L. A. Smith, and M. D. Bradley, “Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials,” British Medical Journal, vol. 325, no. 7365, pp. 619–623, 2002. View at Google Scholar · View at Scopus
  64. F. Díaz-González and F. Sánchez-Madrid, “Inhibition of leukocyte adhesion: an alternative mechanism of action for anti-inflammatory drugs,” Immunology Today, vol. 19, no. 4, pp. 169–172, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Duley, D. J. Henderson-Smart, M. Knight, and J. F. King, “Antiplatelet agents for preventing pre-eclampsia and its complications,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD004659, 2004. View at Google Scholar · View at Scopus
  66. C. Fenton, G. M. Keating, and A. J. Wagstaff, “Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain,” Drugs, vol. 64, no. 11, pp. 1231–1261, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. F. D. Hart and E. C. Huskisson, “Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use,” Drugs, vol. 27, no. 3, pp. 232–255, 1984. View at Google Scholar · View at Scopus
  68. C. J. Hawkey, “COX-2 inhibitors,” The Lancet, vol. 353, no. 9149, pp. 307–314, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. L. A. García Rodríguez, C. Varas-Lorenzo, A. Maguire, and A. González-Pérez, “Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population,” Circulation, vol. 109, no. 24, pp. 3000–3006, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Ma, P. Del Soldato, and J. L. Wallace, “Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 13243–13247, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Charlier and C. Michaux, “Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs,” European Journal of Medicinal Chemistry, vol. 38, no. 7-8, pp. 645–659, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. G. A. FitzGerald, “COX-2 and beyond: approaches to prostaglandin inhibition in human disease,” Nature Reviews Drug Discovery, vol. 2, no. 11, pp. 879–890, 2003. View at Google Scholar · View at Scopus
  73. G. A. FitzGerald and C. Patrono, “The coxibs, selective inhibitors of cyclooxygenase-2,” New England Journal of Medicine, vol. 345, no. 6, pp. 433–442, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. H. F. Cheng and R. C. Harris, “Cyclooxygenases, the Kidney, and Hypertension,” Hypertension, vol. 43, no. 3, pp. 525–530, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Patrono and M. J. Dunn, “The clinical significance of inhibition of renal prostaglandin synthesis,” Kidney International, vol. 32, no. 1, pp. 1–12, 1987. View at Google Scholar · View at Scopus
  76. J. V. Ryn, G. Trummlitz, and M. Pairet, “COX-2 selectivity and inflammatory processes,” Current Medicinal Chemistry, vol. 7, no. 11, pp. 1145–1161, 2000. View at Google Scholar · View at Scopus
  77. H. Schworer and G. Ramadori, “Treatment of acute gouty arthritis with the 5-hydroxytryptamine antagonist ondansetron,” Clinical Investigator, vol. 72, no. 10, pp. 811–813, 1994. View at Google Scholar · View at Scopus
  78. W. L. Smith, D. L. DeWitt, and R. M. Garavito, “Cyclooxygenases: structural, cellular, and molecular biology,” Annual Review of Biochemistry, vol. 69, pp. 145–182, 2000. View at Publisher · View at Google Scholar · View at Scopus
  79. D. L. Scott and R. H. Palmer, “Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety,” Alimentary Pharmacology and Therapeutics, vol. 14, no. 4, pp. 443–452, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. C. N. Serhan and E. Oliw, “Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways,” Journal of Clinical Investigation, vol. 107, no. 12, pp. 1481–1489, 2001. View at Google Scholar · View at Scopus
  81. D. M. Slater, S. Zervou, and S. Thornton, “Prostaglandins and prostanoid receptors in human pregnancy and parturition,” Journal of the Society for Gynecologic Investigation, vol. 9, no. 3, pp. 118–124, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. J. R. O'Dell, “Therapeutic strategies for rheumatoid arthritis,” New England Journal of Medicine, vol. 350, no. 25, pp. 2591–2630, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. N. J. Olson and C. M. Stein, “New drugs for rheumatoid arthritis,” The New England Journal of Medicine, vol. 350, pp. 2167–2179, 2004. View at Publisher · View at Google Scholar
  84. J. R. Vane and R. M. Botting, “Mechanism of action of nonsteroidal anti-inflammatory drugs,” American Journal of Medicine A, vol. 104, supplement 3, no. 2S, p. 8S, 1998. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Ouellet and M. D. Percival, “Mechanism of acetaminophen inhibition of cyclooxygenase isoforms,” Archives of Biochemistry and Biophysics, vol. 387, no. 2, pp. 273–280, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. C. D. Breder, D. Dewitt, and R. P. Kraig, “Characterization of inducible cyclooxygenase in rat brain,” Journal of Comparative Neurology, vol. 355, no. 2, pp. 296–315, 1995. View at Google Scholar · View at Scopus
  87. J. N. Topper, J. Cai, D. Falb, and M. A. Gimbrone Jr., “Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 19, pp. 10417–10422, 1996. View at Google Scholar · View at Scopus
  88. M. Asif, “General study of pyridazine compounds against cyclooxygenase enzyme and their relation with analgesic, anti-inflammatory and anti-arthritic activities,” Chronicles of Young Scientists, vol. 1, no. 3, pp. 3–9, 2010. View at Google Scholar
  89. R. Vinegar, J. F. Truax, J. L. Selph, P. R. Johnston, A. L. Venable, and K. K. McKenzie, “Pathway to carrageenan-induced inflammation in the hind limb of the rat,” Federation Proceedings, vol. 46, no. 1, pp. 118–126, 1987. View at Google Scholar · View at Scopus
  90. M. Yin, Y. Yamamoto, and R. B. Gaynor, “The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β,” Nature, vol. 396, no. 6706, pp. 77–80, 1998. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Brooks, P. Emery, J. F. Evans et al., “Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2,” Rheumatology, vol. 38, no. 8, pp. 779–788, 1999. View at Google Scholar · View at Scopus
  92. V. K. Chintakunta, V. Akella, M. S. Vedula et al., “3-O-Substituted benzyl pyridazinone derivatives as COX inhibitors,” European Journal of Medicinal Chemistry, vol. 37, no. 4, pp. 339–347, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Amann and B. A. Peskar, “Anti-inflammatory effects of aspirin and sodium salicylate,” European Journal of Pharmacology, vol. 447, no. 1, pp. 1–9, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. P. W. Armstrong, D. Collen, and E. Antman, “Fibrinolysis for acute myocardial infarction: the future is here and now,” Circulation, vol. 107, no. 20, pp. 2533–2537, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Costas, P. Besada, A. Piras et al., “New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 22, pp. 6624–6627, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. H. M. Refaat, O. M. Khalil, and H. H. Kadry, “Synthesis and anti-inflammatory activity of certain piperazinylthienylpyridazine derivatives,” Archives of Pharmacal Research, vol. 30, no. 7, pp. 803–811, 2007. View at Google Scholar · View at Scopus